EU regulator warns on waning success of antibody-dependent Covid medicines

BRUSSELS, Dec 9 — The European Union’s overall health regulator has suggested the use of antiviral remedies above monoclonal antibodies to deal with Covid-19 in patients at possibility of their condition worsening, citing concerns around decreasing effectiveness in opposition to newer virus variants.

“(The accredited) monoclonal antibodies are built to neutralise the virus by binding to the spike protein on its floor. Nonetheless, rising strains have mutations in this protein which can lower the potential of the antibodies to bind to them,” the European Medications Agency (EMA) explained.

The Crisis Job Pressure of the EMA explained healthcare industry experts need to test variants circulating in their location and think about alternatives like Pfizer’s Paxlovid and Gilead’s remdesivir. — Reuters